• Return to Headlines

Upgrade Alert for AEterna Zentaris (AEZS)

By Amy Schwartz

AEterna Zentaris (NASDAQ:AEZS) was upgraded from Neutral to Buy at H.C. Wainwright today. The stock closed yesterday at $0.54 on volume of 2.7 million shares, below average daily volume of 2.9 million.

AEterna Zentaris share prices have moved between a 52-week high of $1.54 and a 52-week low of $0.48 and closed yesterday at 12% above that low price at $0.54 per share. Over the past week, the 200-day moving average (MA) has gone down 1% while the 50-day MA has remained constant.

AEterna Zentaris Inc is a biopharmaceutical company focused in oncology and endocrine therapy. The Company's portfolio includes an orally-active inhibitor for multiple cancers, as well a product marketed for in vitro fertilization. AEterna Zentaris also develops and sells active ingredients, specialty chemicals, cosmetic, and nutritional products.

AEterna Zentaris (NASDAQ:AEZS) has potential upside of 151.9% based on a current price of $0.54 and analysts' consensus price target of $1.36. AEterna Zentaris shares should first meet resistance at the 50-day moving average (MA) of $0.57 and find additional resistance at the 200-day MA of $0.89.

SmarTrend is tracking the current trend status for AEterna Zentaris and will alert subscribers who have AEZS in their portfolio or watchlist when shares have changed trend direction.

Keywords: analyst upgrades/downgrades aeterna zentaris

Ticker(s): AEZS